Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 USD | +12.68% | +12.99% | +75.82% |
May. 31 | Health Care Stocks Climb On Drug News -- Health Care Roundup | DJ |
May. 31 | Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program | DJ |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 328.8 | 191.1 | 178.7 | 199.8 | 510.4 | - | - |
Enterprise Value (EV) 1 | 328.8 | 191.1 | 178.7 | 199.8 | 325.4 | 451.1 | 452.4 |
P/E ratio | -6 x | -3.66 x | -3.01 x | -5.42 x | -6.13 x | -3.72 x | -3.35 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 18.7 x |
EV / Revenue | - | - | - | - | - | - | 16.6 x |
EV / EBITDA | - | - | -4.94 x | -4.82 x | -4.26 x | -5.01 x | -5.08 x |
EV / FCF | - | - | -4,892,455 x | - | - | - | - |
FCF Yield | - | - | -0% | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 15,356 | 17,710 | 43,269 | 43,906 | 63,802 | - | - |
Reference price 2 | 21.41 | 10.79 | 4.130 | 4.550 | 8.000 | 8.000 | 8.000 |
Announcement Date | 3/4/21 | 3/25/22 | 3/14/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 27.23 |
EBITDA 1 | - | - | -36.21 | -41.45 | -76.31 | -90.07 | -89.04 |
EBIT 1 | -42.8 | -50.46 | -36.53 | -41.76 | -78.94 | -119.2 | -136.5 |
Operating Margin | - | - | - | - | - | - | -501.24% |
Earnings before Tax (EBT) 1 | -42.48 | -50.64 | -35.36 | -36.95 | -74.89 | -129.4 | -155.9 |
Net income 1 | -42.48 | -50.64 | -35.36 | -36.95 | -77.4 | -137.9 | -169.1 |
Net margin | - | - | - | - | - | - | -621% |
EPS 2 | -3.570 | -2.950 | -1.370 | -0.8400 | -1.306 | -2.150 | -2.387 |
Free Cash Flow | - | - | -36.53 | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 3/4/21 | 3/25/22 | 3/14/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | - | - | - | - | -14.08 | -16.65 | -18.71 | -19.27 | -21.69 | - | - |
EBIT 1 | -9.086 | -8.887 | -8.687 | -8.513 | -10.44 | -7.637 | -9.62 | -10.34 | -14.16 | -16.73 | -18.77 | -21 | -23.49 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -9.134 | -8.943 | -8.667 | -8.32 | -9.425 | -6.526 | -8.366 | -9.064 | -12.99 | -14.65 | -17.7 | -19.88 | -22.66 | - | - |
Net income 1 | -9.134 | -8.943 | -8.667 | -8.32 | -9.425 | -6.526 | -8.366 | -9.064 | -12.99 | -14.65 | -18.05 | -20.94 | -23.75 | - | -35 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.5000 | -0.4900 | -0.4700 | -0.3700 | -0.2100 | -0.1500 | -0.1900 | -0.2100 | -0.2900 | -0.2700 | -0.3250 | -0.3450 | -0.3825 | -0.4700 | -0.5267 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/25/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/14/23 | 5/15/23 | 8/10/23 | 11/14/23 | 3/14/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | - | 185 | 59.3 | 58 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | -36.5 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | -40.3% | - | -51.5% | -55.9% | -109% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | 0.06 | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/4/21 | 3/25/22 | 3/14/23 | 3/14/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.82% | 510M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- LRMR Stock
- Financials Larimar Therapeutics, Inc.